Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    LM PAY

    MCap

    EUR24m

    Last close

    EUR37.60

    ▲ 4.00 (11.90%)

    Northern Data Group

    MCap

    EUR609m

    Last close

    EUR9.48

    ▲ 0.98 (11.47%)

  • Sectors

    Sectors

    View All Sectors
  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sparks commentary

Healthcare

Sparks

SynAct Pharma (STO: SYNACT) launches Phase II trial in dengue
Published by Arron Aatkar, PhD

SynAct Pharma has announced the launch of its exploratory Phase II trial, RESOVIR-2, which has been designed to evaluate the safety and efficacy of resomelagon in patients with dengue, a viral infection. RESOVIR-2 is a randomised and placebo-controlled study, assessing once-daily oral dosing of resomelagon compared to placebo (1:1 randomisation, n=120) as an adjuvant to the standard of care. It has been initiated and is being led by professor Mauro Teixeira, MD, PhD Universidade Federal de Minas Gerais, Belo Horizonte at clinical sites in Brazil. Recruitment, as well as anticipated completion of the trial, will be contingent on the severity of the dengue epidemic.

Next Sparks Commentary in this sector >

Latest

Healthcare | Comment

Mendus (OMX: IMMU) – DIVA opens a new AML front

Consumer | Comment

Games Workshop Group (LSE:GAW) Q127 trading update and dividend

Investment Companies | Comment

IP Group (LSE: IPO) publishes half-year results

Healthcare | Comment

Basilea (SIX: BSLN) advances Cresemba’s Japanese lifecycle

Healthcare | Comment

Mendus (OMX: IMMU) extends cash runway to Q227
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.